Research map: Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib

Back to the article

Papers in this map

  1. Targeting the DNA Damage Response in Cancer · Mark J. O’Connor · 2015 · 1580 citations · Cited by this paper
  2. Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment · Bhaumik Arvindkumar Shah · 2025 · 16 citations · Cites this paper
  3. Transcriptome signatures for the identification of bevacizumab responders in ovarian cancer · 2026 · Related
  4. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer · Melinda L. Telli · 2016 · 1198 citations · Cited by this paper
  5. Homologous recombination deficiency among patients with germline or somatic non-BRCA1/2 homologous recombination repair gene variations · Yue Li · 2025 · 12 citations · Cites this paper
  6. Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience · 2026 · Related
  7. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial · Paul DiSilvestro · 2022 · 510 citations · Cited by this paper
  8. Extrachromosomal circular DNA expressing miRNA promotes ovarian cancer progression · Ning Wu · 2025 · 3 citations · Cites this paper
  9. Integrative stratification of response to immunotherapy using host and microbial signatures in patients with advanced non-small cell lung cancer · 2026 · Related
  10. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer · Rowan E. Miller · 2020 · 504 citations · Cited by this paper
  11. The cGAS–STING pathway in cancer immunotherapy: prognostic value and therapeutic potential · Faizah A. Alabi · 2026 · 3 citations · Cites this paper
  12. Cell type-specific contextualisation of the human phenome: towards the systematic treatment of all rare diseases · 2026 · Related
  13. Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families · Xin Yang · 2019 · 440 citations · Cited by this paper
  14. Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance · Shanza Waseem · 2026 · 2 citations · Cites this paper
  15. Long-read transcriptome sequencing and Drosophila-based functional validation reveal novel gene fusions in fusion panel-negative gliomas · 2026 · Related
  16. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial · Susana Banerjee · 2021 · 386 citations · Cited by this paper
  17. Validation of the SOPHiA DDM HRD Solution as a Companion Diagnostic for Poly (ADP-Ribose) Polymerase Inhibitor Access in Australia · ANDREW P. FELLOWES · 2025 · 2 citations · Cites this paper
  18. Comprehensive genomic characterization of extraintestinal pathogenic Escherichia coli isolated from neonates: multiple center insights into virulence, resistance, and transmission dynamics · 2026 · Related
  19. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial · I. Ray-Coquard · 2023 · 368 citations · Cited by this paper
  20. A Novel Droplet Digital PCR Assay for BRCA1 and RAD51C Methylation · Cassandra Michel · 2025 · 1 citation · Cites this paper
  21. Infiltrating monocyte-derived macrophages does not survive long term in stroke brain despite their dominance in the acute ischemic core and myeloid derived IGF-1 play dichotomous roles in stroke recovery · 2026 · Related
  22. Homologous Recombination Deficiency: Concepts, Definitions, and Assays · Mark D. Stewart · 2022 · 240 citations · Cited by this paper
  23. Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer · Eirini Papadopoulou · 2025 · 1 citation · Cites this paper
  24. Untitled · Cited by this paper
  25. Mutações nos genes BRCA1 e BRCA2 em câncer de mama e ovário entre mulheres: uma revisão sistemática · Ines Nalita D’avila de Lima Alencar · 2025 · 1 citation · Cites this paper
  26. Untitled · Cited by this paper
  27. High-throughput mapping of 6,888 RAD51D variants identifies distinct biochemical functions needed for homologous recombination and olaparib response · Kristie E. Darrah · 2026 · 1 citation · Cites this paper
  28. Untitled · Cited by this paper
  29. Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis · Susanne A. Gatz · 2026 · 1 citation · Cites this paper
  30. Untitled · Cited by this paper
  31. Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian cancer: Expression and clinicopathological correlations · Chen-Lu Zhao · 2026 · Cites this paper
  32. Untitled · Cited by this paper
  33. Homologous Recombination Deficiency Among Patients with Germline or Somatic non-BRCA1/2 Homologous Recombination Repair Gene Variations · Yue Li · 2025 · Cites this paper
  34. Untitled · Cited by this paper
  35. Structure-driven design and precision translation of functionally diverse isatin-based CDK2 inhibitors: Advances in SAR, polypharmacology, and biomarker-guided cancer therapy · Safia Obaidur Rab · 2025 · Cites this paper
  36. Untitled · Cited by this paper
  37. Vasculogenic mimicry-related gene subtypes and a six-gene prognostic signature reveal immune heterogeneity in ovarian cancer · Yan Wang · 2026 · Cites this paper
  38. Untitled · Cited by this paper
  39. LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting · Nicoletta Bonci · 2026 · Cites this paper

Source: OpenAlex (CC0)